Monthly Archives: October 2016

Low T3 associated with worse health measures in hypothyroid patients.

A highlight in the concepts that I gathered at 2016 American Thyroid Association meeting in Denver Colorado includes the documentation that low T3 is associated with worse health measures and for the persistent hypothyroid symptoms in patients treated with levothyroxine

Posted in Hormone Replacement Therapy, hypothyroid, Thyroid, thyroid cancer, Uncategorized

2016 update on thyroid cancer management and diagnosis of risks with molecular markers.

In this blog I will share with you what’s new in papillary thyroid cancer therapy this year: 2016 update on risk stratification for treatment and defining a spectrum with three broad levels of cancer recurrence risk (low, intermediate, high risk)

Posted in Cancer, Thyroid, thyroid cancer

Hypoparathyroidism: Dr. B. Olson’s 2016 update

During the 2016 ATA meetings, I gave a dinner lecture, to endocrinologists, on the use of Natpara on behalf of Shire. Shire is the company that makes this hormone. Natpara is the only FDA approved “bioidentical” parathyroid homone 1-84 that

Posted in Bone Health, Hormone Replacement Therapy, parathyroid, Thyroid, Uncategorized

A lower T3 is associated with a longer life.

A lower T3 in healthy individuals is associated with a longer life. Lower t3 and T4 and higher TSH (blood test that lean toward mild hypothyroids) are associated with a longer life. Supporting Facts are :1)The lower the t4 the

Posted in Lifestyle, Nutrition & Weight, Thyroid, Uncategorized, Wellness & Prevention